About Transcription initiation factor TFIID subunit 9
Transcription initiation factor TFIID subunit 9 (TAF9) is a protein
from Homo sapiens identified by UniProt accession
Q16594, 264 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Transcription initiation factor TFIID subunit 9 |
|---|
| UniProt accession | Q16594 |
|---|
| Gene | TAF9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 264 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.58
- breast adenocarcinoma · score 0.26
- neurodegenerative disease · score 0.19
- lung adenocarcinoma · score 0.19
- head and neck squamous cell carcinoma · score 0.18
- non-alcoholic fatty liver disease · score 0.07
- uric acid measurement · score 0.06
- interleukin 18 measurement · score 0.05
- glomerular filtration rate · score 0.05
- Systemic lupus erythematosus · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16594-F1 | alphafold | PREDICTED | 66.65 | — |
Amino-acid sequence (264 residues)
MESGKTASPK SMPKDAQMMA QILKDMGITE YEPRVINQML EFAFRYVTTI LDDAKIYSSH AKKATVDADD VRLAIQCRAD QSFTSPPPRD FLLDIARQRN QTPLPLIKPY SGPRLPPDRY CLTAPNYRLK SLQKKASTSA GRITVPRLSV GSVTSRPSTP TLGTPTPQTM SVSTKVGTPM SLTGQRFTVQ MPTSQSPAVK ASIPATSAVQ NVLINPSLIG SKNILITTNM MSSQNTANES SNALKRKRED DDDDDDDDDD YDNL
Explore Transcription initiation factor TFIID subunit 9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets